إسرائيل - العربية - Ministry of Health

sanofi - aventis israel ltd - ramipril 2.5 mg - tablets - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - atenolol 100 mg - tablets - atenolol - management of angina pectoris and hypertension,including hypertension of renal origin. late intervention after acute myocardial infarction.

إسرائيل - العربية - Ministry of Health

abic ltd. - atenolol 50 mg - tablets - atenolol - management of angina pectoris and hypertension, including hypertension of renal origin. late intervention after acute myocardial infarction

إسرائيل - العربية - Ministry of Health

sanofi - aventis israel ltd - hydrochlorothiazide 12.5 mg; ramipril 2.5 mg - tablets - ramipril and diuretics - essential hypertension. tritace comp is indicated in patients whose blood pressure cannot be adequately lowered with ramipril alone.

إسرائيل - العربية - Ministry of Health

abic ltd. - atenolol 25 mg - tablets - beta blocking agents, selective - management of angina pectoris and hypertension, including hypertension of renal origin. late intervention after acute myocardial infarction.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - felodipine 2.5 mg - tablets extended release - felodipine - hypertension. angina pectoris.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - ramipril 5 mg - tablets - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

إسرائيل - العربية - Ministry of Health

dexcel pharma technologies ltd - losartan potassium 50 mg - tablets - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric